Can the characteristic odor in patients with Maple Syrup Urine Disease (MSUD) come from sweat?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 22, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can the Characteristic Odor in MSUD Come from Sweat?

Yes, the characteristic maple syrup or burned sugar odor in Maple Syrup Urine Disease (MSUD) is present in sweat, along with urine and cerumen (earwax), as the volatile branched-chain ketoacids are excreted through multiple body fluids.

Sources of the Characteristic Odor

The pathognomonic sweet odor in MSUD originates from the accumulation of branched-chain ketoacids (BCKAs), which are volatile compounds that can be detected in multiple body secretions 1:

  • Sweat and body odor: The burned sugar or maple syrup smell emanates from the patient's body and skin, as documented in multiple case reports where clinicians noted the odor "from the body" in addition to urine 2
  • Urine: The most commonly recognized source, where the odor is typically most concentrated 1, 2
  • Cerumen (earwax): Another characteristic location where the sweet odor can be detected 1

Clinical Recognition and Diagnostic Value

The odor serves as an important clinical clue, particularly in the neonatal period 2:

  • Early presentation: The peculiar burned sugar smell from both body and urine was noted in infants as young as 10-20 days of age, often accompanying other symptoms like poor feeding, vomiting, and convulsions 2
  • Metabolite responsible: One of the branched-chain amino acids (isoleucine) produces a metabolite that causes this distinctive maple syrup smell 3
  • Detection timing: The odor becomes apparent when branched-chain amino acids (leucine, isoleucine, valine) and their corresponding ketoacids accumulate in plasma, urine, and cerebrospinal fluid 4

Biochemical Mechanism

The odor results from deficient activity of the branched-chain α-ketoacid dehydrogenase (BCKAD) enzymatic complex 5:

  • Metabolic block: BCAAs are normally transaminated to BCKAs, but the enzyme required to metabolize the BCKAs is deficient, resulting in elevation of both BCAAs and BCKAs 3
  • Volatile compounds: These accumulated BCKAs are volatile and lipophilic, allowing them to be excreted through sweat glands and other secretory pathways 1

Clinical Pitfall to Avoid

Do not rely solely on detecting the odor in urine—examine the patient's body and skin directly, as the odor may be more readily apparent from sweat, particularly in the early neonatal period when diagnostic suspicion is critical 2. The presence of this odor from any body fluid (sweat, urine, or cerumen) should prompt immediate plasma amino acid analysis and metabolic evaluation 1.

References

Research

Maple syrup urine disease: mechanisms and management.

The application of clinical genetics, 2017

Research

Maple syrup urine disease: report of two cases.

Journal of the Formosan Medical Association = Taiwan yi zhi, 1993

Research

Maple syrup urine disease: Characteristics of diagnosis and treatment in 45 patients in Chile.

American journal of medical genetics. Part C, Seminars in medical genetics, 2021

Related Questions

What is the diagnosis for a patient presenting with generalized seizure, hypoglycemia, and ketones in the urine with a characteristic odor?
What is the appropriate management for a pediatric patient with elevated allo-isoleucine levels, potentially indicative of a metabolic disorder such as maple syrup urine disease?
What are the possible causes of elevated allo-isoleucine in a patient without Maple Syrup Urine Disease (MSUD)?
What does an isolated increase in urinary excretion of 2,3 dihydroxy-2-methylbutyrate indicate?
What is the origin of the characteristic odor in Maple syrup urine disease?
What is the management and treatment plan for a patient with suspected systemic allergies?
Can an external anal sphincter (EAS) be trained to squeeze closer to baseline function before a fistulotomy is performed with pelvic therapy in a patient with a history of failed LIFT procedure, incontinence, and difficulty maintaining perineal hygiene?
Can pelvic floor therapy help a patient with a history of failed LIFT (Ligation of Intersphincteric Fistula Tract) procedure and no fecal or flatus incontinence, but experiencing a breezier feeling in the fistulotomy site with occasional small amounts of air leakage?
What is the recommended treatment for a patient with microscopic colitis, considering their medical history and potential contributing factors such as nonsteroidal anti-inflammatory drug (NSAID) use?
What are the treatment options at home and follow-up instructions for a patient with a hemorrhoid?
Is it safe to start phentermine (phentermine) on a patient with first degree heart block and right bundle branch block (RBBB)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.